This is an automatically translated article.
Ziv-Aflibercept is used in combination with other drugs to treat metastatic rectal cancer. So what is the dose and precautions when using Ziv-Aflibercept?
1. What is Ziv-Aflibercept?
What is Ziv-Aflibercept? Ziv-Aflibercept is used in combination with irinotecan/5-fluorouracil/folinic acid to treat adult patients with resistant or advanced metastatic rectal cancer following oxaliplatin-containing regimens. Aflibercept acts as a decoy receptor, binding to pre-angiogenic vascular endothelial growth factors (VEGF). This in turn disrupts the binding of VEGF to the receptors and leads to inhibition of tumor angiogenesis and ultimately tumor regression. Ziv-Aflibercept is contraindicated in patients with known hypersensitivity to aflibercept or any of the excipients.
2. Dosage and usage of Ziv-Aflibercept
Ziv-Aflibercept should be used under the supervision of a physician experienced in the use of anticancer medicinal products. The recommended dose of Ziv-Aflibercept is 4 mg/kg body weight, given as an intravenous infusion over 1 hour. Hepatic impairment: There are no formal studies of Ziv-Aflibercept in patients with hepatic impairment. Clinical data suggest that no dose modification of Aflibercept is required in patients with moderate hepatic impairment. There are no data regarding the use of aflibercept in patients with severe hepatic impairment. Renal Impairment: Clinical data suggest that no change in the starting dose is required in patients with mild to moderate renal impairment. There are limited data in patients with severe renal impairment, therefore these patients should be treated with caution.
3. What are the side effects of Ziv-Aflibercept?
Adverse reactions that patients may experience when taking the drug are vascular disorders, hypertension, infection, asthenia, fatigue, weight loss, fever, neutropenia, dehydration, stomatitis, gastritis, diarrhea, proteinuria and pulmonary embolism.
4. Notes when using Ziv-Aflibercept
An increased risk of bleeding, including serious and sometimes fatal bleeding events, has been reported in patients treated with Aflibercept. Patients should be monitored for signs and symptoms of gastrointestinal bleeding and other major bleeding. Aflibercept should not be used in patients with major bleeding. Thrombocytopenia has been reported in patients treated with the drug. Blood counts should be monitored at baseline, before the start of each aflibercept cycle, and when clinically necessary. Fatal gastrointestinal perforation has been reported in patients treated with Aflibercept. Patients should be monitored for signs and symptoms of gastrointestinal perforation. Discontinue Ziv-Aflibercept in case of major bleeding; gastrointestinal perforation, fistula formation; hypertension that is not adequately controlled by antihypertensive therapy or the occurrence of hypertensive encephalopathy; heart failure and reduced ejection fraction; arterial thrombotic events; grade 4 venous thromboembolic events (including pulmonary embolism); nephrotic syndrome or thrombotic microvascular disease; serious hypersensitivity reactions including: bronchospasm, dyspnea, angioedema and anaphylaxis; Severe wounds requiring medical intervention and posterior reversible encephalopathy syndrome (PRES) Ziv-Aflibercept should also be withheld at least 4 weeks before scheduled surgery. Pregnancy: There are no data on the use of Aflibercept in pregnant women. Animal studies have shown reproductive toxicity, because of inhibition of angiogenesis following administration. Therefore, Ziv-Aflibercept should only be used if the potential benefit outweighs the possible risk during pregnancy. Lactation: No studies have evaluated the effects of Ziv-Aflibercept on milk production or its effects on nursing infants. It is not known whether Aflibercept is excreted in human milk. Therefore, a decision to discontinue nursing or discontinue the drug must be made based on the benefits of breastfeeding and the benefits of treatment for the mother. The article has provided general information about the drug Ziv-Aflibercept. If you have any questions or need more information about your medication, you should contact your doctor or pharmacist for advice.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
